H F Fernandez

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. doi request reprint What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, FOB3, Tampa, FL, 337612, USA
    Curr Hematol Malig Rep 11:327-32. 2016
  2. doi request reprint Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia
    Hugo F Fernandez
    Moffitt Cancer Center, Tampa, FL Electronic address
    Clin Lymphoma Myeloma Leuk 15:S70-2. 2015
  3. pmc Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Hematol Oncol 3:36. 2010
  4. ncbi request reprint Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?
    H F Fernandez
    Division of Blood and Marrow Transplant, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
    Bone Marrow Transplant 40:505-13. 2007
  5. pmc Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
    Hugo F Fernandez
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 117:5306-13. 2011
  6. doi request reprint New trends in the standard of care for initial therapy of acute myeloid leukemia
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Hematology Am Soc Hematol Educ Program 2010:56-61. 2010
  7. doi request reprint Induction therapy in acute myeloid leukemia: intensifying and targeting the approach
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Curr Opin Hematol 17:79-84. 2010
  8. pmc Anthracycline dose intensification in acute myeloid leukemia
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    N Engl J Med 361:1249-59. 2009
  9. ncbi request reprint Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:153-7. 2009
  10. pmc Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization
    J Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Bone Marrow Transplant 48:346-50. 2013

Collaborators

Detail Information

Publications14

  1. doi request reprint What Is the Optimal Induction Therapy for Younger Fit Patients With AML?
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, FOB3, Tampa, FL, 337612, USA
    Curr Hematol Malig Rep 11:327-32. 2016
    ..With the finding of potential targetable lesions within these molecular aberrancies, new treatments are emerging to deepen remissions and ultimately improve survival. ..
  2. doi request reprint Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia
    Hugo F Fernandez
    Moffitt Cancer Center, Tampa, FL Electronic address
    Clin Lymphoma Myeloma Leuk 15:S70-2. 2015
    ..This is understated in patients with unfavorable-risk AML, who are usually older and have prior myeloid and/or therapy-related disease and more challenges in curing this disease. ..
  3. pmc Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    J Hematol Oncol 3:36. 2010
    ..However, multivariable analysis did not demonstrate significant differences in overall survival (p = 0.78) or non-relapse mortality (p = 0.6) according to conditioning regimen delivered...
  4. ncbi request reprint Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?
    H F Fernandez
    Division of Blood and Marrow Transplant, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL, USA
    Bone Marrow Transplant 40:505-13. 2007
    ..Finally, we will present novel strategies, which can enhance the anti-lymphoma effect, at the same time reducing toxicity, to improve the outcome of ASCT in NHL patients...
  5. pmc Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
    Hugo F Fernandez
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 117:5306-13. 2011
    ..The addition of a single dose of GO in this setting did not improve outcomes...
  6. doi request reprint New trends in the standard of care for initial therapy of acute myeloid leukemia
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Hematology Am Soc Hematol Educ Program 2010:56-61. 2010
    ..Newer agents targeted to specific molecular abnormalities or survival mechanisms in the leukemic cell are being studied as future additions to the current standard therapy...
  7. doi request reprint Induction therapy in acute myeloid leukemia: intensifying and targeting the approach
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Curr Opin Hematol 17:79-84. 2010
    ..In the present review we will present new data from recently completed trials that have demonstrated advances in the treatment of AML...
  8. pmc Anthracycline dose intensification in acute myeloid leukemia
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    N Engl J Med 361:1249-59. 2009
    ..We evaluated the use of cytarabine plus either standard-dose or high-dose daunorubicin as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to improve overall survival...
  9. ncbi request reprint Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities
    Hugo F Fernandez
    Department of Blood and Marrow Transplantation at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:153-7. 2009
    ..Due to its curative potential, allogenic hematopoietic transplantation (HCT) was a mainstay of treatment for chronic myeloid leukemia (CML), but the advent of tyrosine kinase inhibitors (TKIs) has markedly altered the use of allogeneic HCT...
  10. pmc Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization
    J Pidala
    Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Bone Marrow Transplant 48:346-50. 2013
    ..Further efforts are needed to enhance effective donor identification and transplant utilization, particularly in non-Caucasian ethnic groups...
  11. doi request reprint Sirolimus for treatment of steroid-refractory acute graft-versus-host disease
    D Hoda
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Bone Marrow Transplant 45:1347-51. 2010
    ..Median OS after initiation of sirolimus was 5.6 months, and 1-year OS was 44% (95% CI: 27-60%). Sirolimus is effective in controlling steroid-refractory aGVHD...
  12. doi request reprint Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years
    W E Janssen
    Department of Blood and Marrow Transplant, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Bone Marrow Transplant 47:1520-5. 2012
    ..However, concern over reduced CD34 + cell mobilization may be sufficient grounds to seek younger donors when possible...
  13. doi request reprint 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
    T Field
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Bone Marrow Transplant 45:255-60. 2010
    ..5-Azacitidine may be of value in stabilizing the disease, thereby allowing time for patients to reach transplant and does not appear to affect transplant outcomes...
  14. ncbi request reprint A randomized trial of anthracycline dose intensification during induction of younger patients with acute myeloid leukemia: Results of Eastern Cooperative Oncology Group study E1900
    H F Fernandez
    Moffitt Cancer Center, Tampa, FL Dana Farber Cancer Institute, Boston, MA Mayo Clinic, Rochester, MN University of Pennsylvania, Philadelphia, PA The North Division of Montefiore Medical Center, Bronx, NY Rambam Medical Center, Haifa, Israel University Hospitals of Cleveland, Cleveland, OH Northwestern University, Chicago, IL
    J Clin Oncol 27:7003. 2009
    ..This unresolved issue led the ECOG to compare standard dose (SDD) to high-dose daunorubicin (HDD) in induction...